188 related articles for article (PubMed ID: 35435272)
1. Anakinra treatment efficacy in reduction of inflammatory biomarkers in COVID-19 patients: A meta-analysis.
Naveed Z; Sarwar M; Ali Z; Saeed D; Choudhry K; Sarfraz A; Sarfraz Z; Felix M; Cherrez-Ojeda I
J Clin Lab Anal; 2022 Jun; 36(6):e24434. PubMed ID: 35435272
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of anakinra compared to standard care of treatment for COVID-19: a meta-analysis.
Malık H; Bınt Abdul Jabbar H; Latıf F; Sarfraz A; Sarfraz Z; Sarfraz M
Turk J Med Sci; 2022 Jun; 52(3):547-553. PubMed ID: 36326309
[TBL] [Abstract][Full Text] [Related]
3. Colchicine, COVID-19 and hematological parameters: A meta-analysis.
Sarwar M; Ali Z; Fatima M; Sarfraz Z; Sarfraz A; Cherrez-Ojeda I
J Clin Lab Anal; 2021 Dec; 35(12):e24057. PubMed ID: 34708886
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study.
Aomar-Millán IF; de Victoria-Carazo JM; Fernández Reyes D; Torres-Parejo Ú; Pérez Fernández L; Martínez-Diz S; Ceballos Torres A; López Gómez J; Bizzarri F; Raya Álvarez E; Salvatierra J
PLoS One; 2023; 18(3):e0283529. PubMed ID: 36961847
[TBL] [Abstract][Full Text] [Related]
5. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
6. Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis.
Dahms K; Mikolajewska A; Ansems K; Metzendorf MI; Benstoem C; Stegemann M
Eur J Med Res; 2023 Feb; 28(1):100. PubMed ID: 36841793
[TBL] [Abstract][Full Text] [Related]
7. A meta analysis on the utility of Anakinra in severe COVID-19 disease.
Mohamed Hussein AAR; Sayad R; Abdelshafi A; Hammam IA; Kedwany AM; Elkholy SA; Ibrahim IH
Cytokine; 2023 Sep; 169():156311. PubMed ID: 37536222
[TBL] [Abstract][Full Text] [Related]
8. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.
CORIMUNO-19 Collaborative group
Lancet Respir Med; 2021 Mar; 9(3):295-304. PubMed ID: 33493450
[TBL] [Abstract][Full Text] [Related]
9. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study.
Kooistra EJ; Waalders NJB; Grondman I; Janssen NAF; de Nooijer AH; Netea MG; van de Veerdonk FL; Ewalds E; van der Hoeven JG; Kox M; Pickkers P;
Crit Care; 2020 Dec; 24(1):688. PubMed ID: 33302991
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of clinically relevant serum proteins as biomarkers for monitoring COVID-19 severity, and end-organ damage among hospitalized unvaccinated patients.
Elhommosani MR; Sakr MM; Abbas RM; Aboshanab KM
BMC Infect Dis; 2024 Feb; 24(1):231. PubMed ID: 38378528
[TBL] [Abstract][Full Text] [Related]
11. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
[TBL] [Abstract][Full Text] [Related]
12. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis.
Barkas F; Filippas-Ntekouan S; Kosmidou M; Liberopoulos E; Liontos A; Milionis H
Rheumatology (Oxford); 2021 Dec; 60(12):5527-5537. PubMed ID: 33999135
[TBL] [Abstract][Full Text] [Related]
13. ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients.
Karakike E; Dalekos GN; Koutsodimitropoulos I; Saridaki M; Pourzitaki C; Papathanakos G; Kotsaki A; Chalvatzis S; Dimakopoulou V; Vechlidis N; Paramythiotou E; Avgoustou C; Ioakeimidou A; Kouriannidi E; Komnos A; Neou E; Rovina N; Stefanatou E; Milionis H; Nikolaidis G; Koutsoukou A; Damoraki G; Dimopoulos G; Zoumpos V; Eugen-Olsen J; Akinosoglou K; Gatselis NK; Koulouras V; Gkeka E; Markou N; Netea MG; Giamarellos-Bourboulis EJ
J Innate Immun; 2022; 14(3):218-228. PubMed ID: 34852352
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis.
Melo AKG; Milby KM; Caparroz ALMA; Pinto ACPN; Santos RRP; Rocha AP; Ferreira GA; Souza VA; Valadares LDA; Vieira RMRA; Pileggi GS; Trevisani VFM
PLoS One; 2021; 16(6):e0253894. PubMed ID: 34185801
[TBL] [Abstract][Full Text] [Related]
15. An open label trial of anakinra to prevent respiratory failure in COVID-19.
Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ
Elife; 2021 Mar; 10():. PubMed ID: 33682678
[TBL] [Abstract][Full Text] [Related]
16. Mortality in Patients of COVID-19 Infection: Biochemical Markers and its Cut-off Values for Predicting Outcome.
Yousaf MN; Sarwar S; Tarique S; Ahmed M; Tahir H
J Coll Physicians Surg Pak; 2022 Jan; 32(1):37-41. PubMed ID: 34983145
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis.
Peng J; Fu M; Mei H; Zheng H; Liang G; She X; Wang Q; Liu W
Rev Med Virol; 2022 May; 32(3):e2295. PubMed ID: 34558756
[TBL] [Abstract][Full Text] [Related]
18. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Analytical Values D-Dimer, Glucose, Ferritin and C-Reactive Protein of Symptomatic and Asymptomatic COVID-19 Patients.
Pérez-García N; García-González J; Requena-Mullor M; Rodríguez-Maresca MÁ; Alarcón-Rodríguez R
Int J Environ Res Public Health; 2022 Apr; 19(9):. PubMed ID: 35564749
[TBL] [Abstract][Full Text] [Related]
20. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.
Pasin L; Cavalli G; Navalesi P; Sella N; Landoni G; Yavorovskiy AG; Likhvantsev VV; Zangrillo A; Dagna L; Monti G
Eur J Intern Med; 2021 Apr; 86():34-40. PubMed ID: 33581979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
